Prophylactic vaccines against human papillomavirus (HPV) based on virus-like particles (VLP) induce type-specific neutralizing antibodies against a small number of hypervariable residues positioned in surface-exposed loops of the major capsid protein L1. To investigate the importance of these residues for neutralization, cross-neutralization, L2 incorporation and genome encapsidation, ten surface-exposed amino acid residues in four hypervariable loops of L1 were mutated. VLPs containing mutated or WT L1, with or without WT L2, were produced in 293TT cells using pseudovirion expression vectors. The mutations reduced the ability to induce neutralizing antibodies and to incorporate the L2 protein in the capsid. Ability to induce crossneutralizing antibodies and to encapsidate pseudogenomes were completely abrogated. In summary, the surface-exposed L1 loops are important for the function of the HPV particle.
INTRODUCTION
The genital human papillomaviruses (HPV) cause premalignant lesions of the genital mucosa that may progress to cervical and other anogenital cancers. HPV particles are approximately 55 nm in diameter and are composed of two structural proteins, L1 and L2. The L1 proteins are arranged into pentameric capsomeres (Chen et al., 2000) , and the minor capsid protein L2 is arranged in the middle of the L1 pentamer (Buck et al., 2008; Chen et al., 2000; Lowe et al., 2008) . The major capsid protein L1 has a DNAbinding C-terminal domain (Schäfer et al., 2002) and can encapsidate DNA into virus-like particles (VLPs) also in the absence of L2 (Unckell et al., 1997) . However, the presence of L2 enhances both encapsidation of the 8 kb circular dsDNA viral genome (Buck et al., 2005; Holmgren et al., 2005) and viral particle infectivity (Holmgren et al., 2005) . The L2 protein also participates in multiple steps during papillomavirus entry into host cells (reviewed by Schiller et al., 2010) .
X-ray crystallographic studies have shown distinct structures associated with the variable surface loops that form the crown or apex of the L1 capsomere (Bishop et al., 2007) . The structural diversity present in the L1 protein surface loops among different species of papillomaviruses is believed to reflect the evolution of the virus by mutations that are the molecular mimicry of antigenic diversity. There are two well-characterized mAbs, named HPV16.V5 and HPV16.E70, that are strong, type-specific HPV16 neutralizers with overlapping epitopes (Christensen et al., 1996) . HPV16.V5 binds to the FG-loop of the L1 protein (Carter et al., 2003) and is used as a reference mAb for characterization of VLPs, epitope retrieval (Carter et al., 2003; Carter et al., 2006; Wang et al., 2003) and inhibitionbased HPV serology assays in HPV vaccination trials (reviewed by Schiller & Lowy, 2009 ).
The L1 protein makes up the majority of the surface of the virions and is highly immunodominant over L2. The L2 Nterminal contains amino acid sequences that are highly conserved between distantly related papillomavirus types. Some antibodies targeting this region can cross-neutralize a broad range of papillomaviruses (reviewed by Palmer et al., 2009) . It has been suggested that the major function of the L1 variable loops is to shield the highly conserved domains of L2, which mediate virus entry, from the immune system (Day et al., 2008a, b) . The crystal structure of complete L1 : L2 particles is not available and therefore very little is known about the interactions between L1 and L2. Computer modelling has suggested that L1 FG-and DEloops interact with specific proline-rich regions of L2 (Lowe et al., 2008) .
affecting the secondary structure (Ryding et al., 2007) . In the present study, we produced new mutant constructs that contained these mutations, but were also expressing full-length L1 and were designed for mammalian cell, rather than insect cell, expression. Apart from previously studied issues, such as binding of mutant L1 proteins to neutralizing mAbs and CTL responses (Ryding et al., 2007) , we now also studied whether mutant VLPs expressing fulllength L1 in mammalian cells were able to induce neutralizing antibodies, cross-neutralizing antibodies and whether the mutations affected L2 incorporation and pseudogenome encapsidation.
RESULTS

Characterization of HPV16 capsids
The L1 amino acid substitutions in the HPV16 L1 sequence were inserted into the same positions as previously described (Ryding et al., 2007) . Amino acids in these positions were replaced with amino acids with no or small side chains (glycine, serine or alanine) (Fig. 1a , Table 1 ). The mutated L1 DNA sequence (hereafter abbreviated as the V5 -construct) was chemically synthesized and cloned into expression vectors as described in Methods. Three different HPV16 capsid variants were studied: two of them contained both L1 and L2 proteins (WTL1L2 and V5 2 L1WTL2) and the third only L1 (V5 2 L1).
Production of HPV16 WTL1L2 capsids was twice as effective, in terms of quantity of L1 protein produced, compared with the production of mutated capsids with L2 (V5 2 L1WTL2) and three times more effective than production of capsids V5 2 L1 without L2. Compared with WTL1L2, the L2 content was significantly lower in the mutated capsid V5 2 L1WTL2 (Fig. 2) . A maximum content of L2 in WT capsids is reported to be one L2 molecule per five L1 molecules (Buck et al., 2008) . Indeed, protein concentration determination of protein bands visualized with StainBlue showed an L1 : L2 ratio in WTL1L2 capsids of about one L2 molecule per five L1 molecules, while in the case of V5 2 L1WTL2 it was one per 10 ( Fig. 2a) . Western blot analysis was performed to quantify more precisely and specifically the relative L1 : L2 ratio in the capsids. For that analysis, samples were loaded onto SDS-PAGE by twofold dilutions and membranes were incubated with anti-L1 and L2 antibodies (Fig. 2b ). The L1 : L2 ratio in the WT capsids was about 1.3, whereas in mutated V5 2 L1WTL2 capsids it was 3.2. Thus, both SDS-PAGE and Western blot analysis showed that WT capsids contained about twice as many L2 molecules as mutant V5 2 L1WTL2.
Transmission electron microscopy (TEM) of WTL1L2 capsids (Fig. 3) showed particles that were homogeneous in shape and size (55-60 nm diameter). Mutated capsids varied more in shape and size. In particular, the V5 2 L1 capsid preparations contained a significant amount of smaller particles (diameters around 40 nm). HPV16 WT and mutated V5 2 L1WTL2 pseudovirions carrying the pYSEAP reporter plasmid as pseudogenomes were also produced. The HPV16 WT pseudovirions incorporated pseudogenomes efficiently, as expected . However, the mutated V5 2 L1WTL2 HPV16 pseudovirions did not produce any secreted alkaline phosphotase (SEAP) signal in the neutralization assay, despite the fact that capsids were formed (Fig. 3) and that both L1 and L2 proteins were produced (Fig. 2) . To investigate if the lack of SEAP signal was attributable to a lack of encapsidation of the pseudogenome in these virions, we extracted DNA from pseudovirion preparations and performed SEAP gene-specific PCR. There was a complete absence of the pYSEAP plasmid in the mutant particles (Fig. 4) and therefore we concluded that mutant capsids were not able to encapsidate the pseudogenome.
Characterization of assembly and specific epitopes of capsids Specific epitopes of L1 and L2 proteins were studied to investigate the effect of the mutations in L1 on epitope exposure. The same amounts of HPV16 WT and mutated capsids (quantified by SDS-PAGE; Fig. 2a ) were tested by ELISA, both as intact and as disrupted capsids (also displaying internal epitopes, that may be buried inside intact capsids). Several mAbs specific for known L1 epitopes (Christensen et al., 1996) and monospecific antisera from animals immunized with L1 and L2 peptides (Dillner et al., 1991) were tested. The antibodies selected for this study were directed against epitopes that were likely to be affected (Fig. 1) by the mutations in the L1 loops or changes in the L1-L2 interactions. L1-specific mAbs and sera used in this study (Fig. 1, Table 1 ) were selected according to results from previous studies (Bishop et al., 2007; Carter et al., 2006; Christensen et al., 2001; White et al., 1999) and especially the available L1 crystal structure (Chen et al., 2000) .
Computer models have suggested that the L1 FG-and DEloops interact with a specific proline-rich regions of L2 (Lowe et al., 2008) and we therefore tested the reactivity of antipeptide sera raised against this region of L2 (Fig. 1b , Table 1 ). Also, HPV16 L2-specific antisera were chosen according to the known information about linear epitopes exposed on the virion surface (Embers et al., 2002; Kawana et al., 1999) , experimentally proven L1 binding site (Finnen et al., 2003) and finally, against a cross-neutralizing epitope (Gambhira et al., 2007; Rubio et al., 2011) .
All HPV16 L1-specific mAbs reacted with HPV16 WTL1L2 capsids, as described earlier (Christensen et al., 1996) ( Table 1 ). The reaction of mAbs and antisera with mutated capsids differed compared with the reaction with WT capsids. The mAbs H16.V5 and H16.E70 that are reactive with conformational epitopes of the FG-loop (major neutralizing epitope) (Christensen et al., 1996) bound mutated capsids, but the binding of H16.V5 was reduced to about half and to one-third for H16.E70 (Table 1) compared with WT. A repeat experiment using a 1000-fold higher dilution of H16.V5 found reactivity was reduced about fivefold (Table 1) , emphasizing the fact that singledilution experiments are not quantitative. The H16.V5 and H16.E70 epitopes remained conformational on mutated capsids, as reactivity with disrupted capsids was very low. The epitopes recognized by H16.F18 (DE-loop), A16-6 (BC-loop) and A16-25 (HI-loop) were not found on intact capsids, but were exposed on disrupted capsids (Table 1) . These buried epitopes appeared to be lost in the mutated capsids. The epitopes recognized by H16.I23 (DE-loop), H16.B20 (aa 395-415) and A16-21 (FG-loop) were only weakly exposed on intact WT capsids, but were more exposed on intact capsids expressed from the mutated constructs. The A16-11 that is directed to a linear epitope in the DE-loop appeared to be buried inside WT capsids, but was more exposed on the intact mutated capsids. The opposite phenomenon was found for disrupted capsids, where the reactivity was weaker with mutant capsids. The other mAbs and antisera reactive with linear epitopes of WT HPV16 capsids (H16.C2, H16.O7 -EF-loop, H16.S1 -DE-loop and A16-21 -FG-loop), all reacted similarly with the intact and the disrupted mutated capsids. It is noteworthy that the mutated capsids reacted with EFloop-specific antisera more strongly than WT capsids did, even though there were no substitutions in this region.
L2-specific antisera always reacted more weakly with mutated capsids compared with WT, in line with the lower L2 content in mutated capsids (Table 1) . Also, L2-specific antisera reacted more strongly with WT disrupted capsids than with intact ones, which is in agreement with the fact that the L2 protein is hidden behind L1 molecules in intact capsids. A16-37, directed to the cross-neutralization epitope of L2, reacted only weakly with the studied capsids. 
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Immunization of mice with HPV16 capsids and analysis of immune sera
In order to investigate the antibody induction of HPV16 mutant and WT particles, C57BL/6 mice were immunized with HPV16 capsid variants in PBS/incomplete Freund's adjuvant (IFA) or with PBS/IFA as a negative control. The mice immunized with WT particles demonstrated a higher level of specific antibodies compared with mice immunized with mutant particles (Fig. 5 ). Mice immunized with PBS/ IFA only did not develop antibodies against HPV16, as expected. Antibody levels were higher after the third immunization than after the second immunization for WTL1L2 and V5 2 L1WTL2. Mutant capsids without L2 (V5 2 L1) showed no differences in antibody level before and after the third immunization (data not shown).
To examine the existence and levels of (cross-) neutralizing antibodies in blood serum after immunization, a standard neutralization assay was performed. HPV16, -31, -33, -6, -11 and -18 and bovine papillomavirus type 1 (BPV1) pseudoviruses carrying SEAP-producing pseudogenomes were used as targets. Table 2 shows neutralization titres (0-100 %) of papillomavirus pseudovirions neutralized by pooled sera diluted up to 10 4 -fold. Mice immunized with HPV16 WTL1L2 capsids had a very high level of neutralizing antibodies against HPV16 pseudoviruses. These were neutralized to 100 % even when the serum was diluted 10 4 -fold. Mice immunized with V5 2 L1 capsids neutralized HPV16 pseudovirions up to 10 3 -fold serum dilution. Mice immunized with V5 2 L1WTL2 capsids did not neutralize HPV16 pseudoviruses as well, even when serum was diluted only 10 2 -fold. In serum gathered before the third immunization it was about 75 % and only after the third immunization about 95 %. If the serum was diluted further, it lost its neutralizing abilities. Serum from mice immunized with HPV16 WT capsids had strong cross-neutralizing ability (Table 2) . This serum was able to neutralize HPV31 and HPV33 pseudoviruses in dilution 10 2 -fold to almost 100 %. There were no cross-neutralizing antibodies induced by the mutant VLPs. None of the other HPV pseudovirions tested (HPV6, -11 and -18, BPV1) were neutralized by any one of the mouse sera (data not shown).
Ability of HPV16 capsids to induce CTL response
To test whether mutated HPV16 capsids were able to elicit a CTL response effectively compared to WT, spleens from immunized mice were processed as described in Methods. All cells used in this experiment were derived from C57BL/ 6 mice. Spleens from the same group of mice were pooled together and T-lymphocytes were separated and cocultured with stimulator cells (RMA-S). The C3 cell line, carrying the HPV16 genome, was used as target cells. Results showed that mice immunized with HPV16 WT capsids had up to ten times greater ability to induce the CTL response compared with mutated capsids (Fig. 6) .
DISCUSSION
In the present study we examined the effects of amino acid substitutions in L1 surface loops on capsid formation and immunogenicity. We found that intact L1 surface loops are crucial for proper L2 binding and genome encapsidation. Despite that, the mutations did not destroy the neutralizing epitope completely and mutated capsids were still able to induce neutralizing antibodies, while the CTL response was strongly reduced.
The reason for impaired L2 binding into mutated capsids might be pleiotropic conformational changes in the capsids rather than a direct binding between the L1 surface loops and L2. As we studied 10 aa substitutions at the same time, we cannot determine which residues were most important. As we did not mutate the L1 DNA-binding domain, the defect to encapsidate pseudogenome is most probably attributable to the reduced L2 content in the mutated capsids. The smaller size of mutant capsids is unnecessary to explain the inability for encapsidation as V5-L1WTL2 capsids had a similar size to WT capsids.
In a previous study (Ryding et al., 2007) , a different protein expression system was used (baculovirus expression system) and the L1 lacked the C-terminal 20 aa. These mutated capsids did not bind H16.V5 antibodies, while H16.E70 binding was not affected. Neutralizing antibodies were not produced in mice immunized with mutated capsids. In the present study, the same mutations did not remove the major type-specific conformational neutralizing epitope of HPV16, only reduced the binding to the neutralizing mAbs. As expected when the mutations in the H. Faust and J. Dillner present study did not remove the major neutralizing epitope completely, neutralizing antibodies were also produced in mice immunized with mutated capsids, albeit at lower titres. The fact that HPV31 and HPV33 crossneutralizing antibodies appeared only after immunization WT HPV16 capsids suggests that the major neutralizing epitope may also be responsible for the cross-neutralization. Interestingly, mutant particles containing L2 induced even lower levels of neutralizing antibodies compared with the mutant particles without L2. An explanation for this finding is not obvious.
Although the results from the two studies differed regarding how much the mutations affected the major neutralizing epitope, they agree in the conclusion that these mutations impair the immunogenicity of HPV16 VLPs.
The ideal therapeutic peptide-presenting vector would be a pseudovirion that does not induce neutralizing antibodies against itself, but still elicits the CTL response. The previous study found that CTL responses to mutated CTLs were impaired (Ryding et al., 2007) and this decline in ability to induce CTLs was even more pronounced in the present study, further indicating that it is not possible to modify the humoral immunogenicity without also impairing the cellular immunogenicity.
In conclusion, the studied mutations in L1 loops affected capsid conformation, impaired L2 binding and abolished genome encapsidation. The mutations in L1 surface loops also affected both humoral and cellular immune responses to HPV16 pseudovirions. Our findings imply that targeting the type-specific surface loops to engineer more broadly reactive HPV vaccines will not be possible -even though some neutralizing antibodies were still induced, the crossneutralizing antibodies were entirely abolished. The importance of these residues for the key biological function of the HPV particle such as L2 incorporation and genome encapsidation also suggest that naturally occurring 'escape mutants' will be unlikely.
METHODS
Cell lines and culture conditions. The 293TT cell line was used for virus capsid and pseudovirion production as described previously . Cell lines used for the cytotoxicity assay were of C57BL/6 origin. RMA-S and C3 cells were cultured in RPMI 1640 with L-glutamine (Invitrogen) and supplemented with 5 % FBS, 10 mM 2-mercaptoethanol and in the case of RMA-S antibiotics 1 % penicillin/streptomycin and in the case of C3 0.1 mg kanamycin ml 21 and 0.8 mg gentamicin (G418) ml 21 (all from Invitrogen). Table 2 . Ability to neutralize HPV pseudovirions
Mice were immunized three times, and pooled serum was tested after the second and third immunization. Sera were diluted 1 : 10 2 -, 1 : 10 3 -and 1 : 10 4 -fold. Data shown are the percentages of virus neutralization. NT, Not tested. None of the other HPV pseudovirions tested (HPV6, -11 and -18, BPV1) were neutralized by any of the mouse sera. Bold indicates neutralization of more than 50 %.
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Plasmids. HPV L1 and L2 expressing vectors were kindly provided by Christopher Buck and John Schiller . Nucleotide sequences of those plasmids can be found at: http://home.ccr.cancer. gov/lco/default.asp. The following plasmids were used to generate HPV pseudovirions: pShell, p6Shell, p11L1w, p11L2w, p16Shell, p18Shell, p31Shell and pYSEAP reporter plasmid. A new p33Shell plasmid was generated by cloning modified and chemically synthesized HPV33 L1 and L2 genes into the p5Shell vector. The nucleotide sequence of HPV33 (GenBank accession no. M12732) was codonmodified using the principles previously described by Buck et al. (2004) and elaborated at http://home.ccr.cancer.gov/lco/codonmodification. htm. The genes were chemically synthesized by Blue Heron Biotechnologies, confirmed by cloning and sequencing using the restriction enzymes BspEI and PspXI (for L1) and NotI and NheI (for L2) to replace HPV5 L1 and L2 from p5Shell vector with HPV33 genes.
To generate HPV16 capsids with amino acid substitutions in the L1 surface loops, the L1 gene was modified and chemically synthesized by Blue Heron. The modified gene was confirmed by sequencing and cloned using the restriction enzymes EagI and EcoNI to replace the original L1 coding sequence in p16L1h with the modified gene. The new plasmid was called p16V5 2 H. To clone the modified L1 gene into the L1 and L2 expression vector p16Shell, an AflII restriction site was added by PCR. AflII and PpuMI restriction enzymes were utilized to replace the original L1 sequence with the modified one in the bicistronic vector. The new plasmid was called p16V5 2 Shell. It was used to produce mutant HPV16 capsids and pseudovirions with pYSEAP reporter as the pseudogenome.
Generation of viral capsids and pseudovirions. The HPV viral capsids and pseudovirions were generated by transfection of 293TT cells as described elsewhere . Virus particles were adsorbed onto carbon-coated grids, stained with uranyl formate and examined with transmission electron microscopy (TEM). For mouse immunization, pseudovirions collected by ultracentrifugation were purified on an agarose gel column to remove the centrifugation solution and achieve excellent purity as described at http://home.ccr. cancer.gov/lco/gelfiltration.htm. To quantify the density of the protein bands, Quantity One version 4.6.3 software (Bio-Rad) was used.
Western blot analysis. Reduced capsid samples were run on 10 % NuPage Bistris gels (Invitrogen) and blotted onto nitrocellulose membrane (Millipore). Membranes were blocked with 5 % non-fat dried milk (Bio-Rad) in PBS (pH 7.2) supplemented with 0.05 % Tween 20 (Sigma) and incubated with anti-HPV16 L1 (A16-19A) and L2 (A16-60) monospecific antipeptide antibodies at a dilution of 1 : 1000. Following incubation with HRP-conjugated anti-rabbit IgG (GE Healthcare) at a dilution of 1 : 10 000, membranes were developed with the ECL system (Pierce). To quantify the density of the protein bands, Quantity One version 4.6.3 (Bio-Rad) software was used.
DNA extraction from pseudovirions and PCR. For the 10 ml (c.200 ng) pseudovirion preparation (HPV16 WT and V5 2 ) 30 ml lysis buffer [10 mM Tris/HCl (pH 7.8), 10 mM NaCl, 10 mM EDTA, 4 % SDS, 250 mg proteinase K ml 21 ] with proteinase K (Roche) was added and incubated at 37 uC overnight. After incubation, 15 ml saturated NH 4 Ac was added to the samples, and was mixed and centrifuged at 13 000 g for 15 min at 4 uC. The supernatant was transferred to a new tube and 90 ml cold 99 % ethanol was added. DNA was precipitated at 220 uC for 30 min. Samples were centrifuged at 13 000 g for 5 min at 4 uC and the pellet was washed with 100 ml 70 % ethanol. The DNA was dried and dissolved in 20 ml Tris-EDTA buffer (in-house produced Tris-EDTA).
PCR was performed using AmpliTaq Gold reagents (Roche). Final concentration of reagents for the 25 ml reaction were 16 PCR buffer II, 1 mM MgCl 2 , 250 mM dNTPs, 1.25 U AmpliTaq Gold polymerase and 10 pmol primers. Primers were SEAP gene-specific SEAPFw 59-GACAGCTGCCAGGATCCTA-39and SEAPRev 59-CAGCTTGGCT-GTAGTCATC-39. As templates, 5 ml extracted DNA from pseudovirions and 200 ng pYSEAP plasmid (positive control) were used. PCR without template was used as a negative control. The PCR cycle used was 95 uC 5min, 95 uC 1 min, 55 uC 1 min, 72 uC 1 min, 72 uC 5 min. Steps 2-4 were repeated 25 times. PCR products were analysed on 1 % agarose gel by electrophoresis.
Mouse immunization. Female C57BL/6 mice (8-12 weeks old; Taconic M&B) were injected subcutaneously with 10 mg pseudovirions containing HPV16 WT L1 and L2 (WTL1L2) proteins, modified L1 (V5 2 L1) protein only and modified L1 and WT L2 (V5 2 L1WTL2) proteins. Immunogens were administrated with an equal volume of incomplete Freund's adjuvant (IFA) (100 ml of both). A group of control mice was injected with pseudovirion purification buffer (PBS with 0.5 M NaCl, 0.01 % Polysorbat 80, pH 7.2; Sigma) and IFA. Each group consisted of five mice, which were immunized three times at 4 week intervals. The mice were bled through the vena saphena before the third immunization (week 10) and after termination (week 12). Spleens of immunized mice were collected after termination, pooled and utilized in the CTL assay. Ethical permission to perform animal experiments was gained from the Swedish Board of Agriculture, diary number M208-04 (20041119).
ELISA. ELISA half-area plates were coated overnight at 4 uC with HPV16 capsids diluted in cold PBS (pH 7.2) at a concentration of 2 mg ml
21
, 50 ng capsids per well. Disrupted capsids were generated through incubation at room temperature for 4 h in carbonate buffer (pH 9.6). The plates were washed five times with PBS/0.5 % Tween 20 (PBS-T), after which they were blocked with PBS supplemented with horse serum (10 % HS-PBS) at room temperature for 1 h. Blocking solution was removed from the wells and mABs (1 : 1000 dilution) or sera (1 : 50) diluted in HS-PBS was added followed by incubation for 1 h. After washing the plates five times with PBS-T, HRP conjugate diluted 1 : 1000 in HS-PBS was added for 1 h incubation. Depending of the mAb or serum used, HRP was conjugated to goat anti-mouse IgG (Southern Biotech) or rabbit anti-guinea pig immunoglobulin (Dako). Citrate buffer (0.1M) containing 16 ABTS [2,29-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)] and 0.01 % H 2 O 2 was added to the plates for colour development after the final wash (five times with PBS-T). Absorbance was read after 20 min development at 405 nm.
Neutralization assay. Pseudovirions with encapsidated secreted alkaline phosphotase (SEAP)-expressing reporter plasmid as pseudogenome were utilized in a neutralization assay as described by Pastrana et al. (2004) . Samples were read in white Chromalux HB flat-bottomed microplates (Dymex) for 0.2 s per well using a Wallac Victor 1420 multilabel counter. Serum neutralization titres were defined as the reciprocal of the highest dilution that caused at least a 50 % reduction in SEAP activity.
Cytotoxicity assay. Spleens were collected from the C57BL/6 mice (immunized as described under 'Mouse immunization') and pooled. Lymphocytes were isolated from spleens using a Nylon Fibre Column T (Wako) following the manufacturer's recommendations. Stimulator (RMA-S) and spleen cells (1 : 10 ratio) were transferred to 24-well plates in medium containing RPMI 1640 with L-glutamine, 10 % FBS, 1 mM sodium pyruvate, 50 mM 2-mercaptoethanol, 10 mM HEPES and 0.1 mg gentamicin ml 21 (Invitrogen). Cells were co-cultured for 5 days, and 5 ng interleukin-2 ml 21 (Chiron) was added to the wells on day 3. On day 5, T-lymphocytes were separated by centrifugation with Lympholyte M (Cederlane Laboratories). Specific cytolytic activity was determined by CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) according to the manufacturer's recommendations. C3
